Efficacy and Safety of IDegLira Versus Basal-Bolus Insulin Therapy in Patients With Type 2 Diabetes Uncontrolled on Metformin and Basal Insulin: The DUAL VII Randomized Clinical Trial.
Liana K BillingsAnkur DoshiDidier GouetAlejandra OviedoHelena W RodbardNikolaos TentolourisRandi GrønNatalie HalladinEsteban JodarPublished in: Diabetes care (2018)
In patients with uncontrolled type 2 diabetes on IGlar U100 and metformin, IDegLira treatment elicited HbA1c reductions comparable to basal-bolus, with statistically superior lower hypoglycemia rates and weight loss versus weight gain.